Catalyzing Pharmacogenomic Analysis for Informing Pain Treatment (C-PAIN): A Randomized Trial of Preemptive CYP2D6 Genotyping in Cancer Palliative Care
Youngwoo Cho,Theodore Karrison,Matthew Jack,Anish Choksi,Randall Knoebel,Kiang-Teck Yeo,Samuel Volchenboum,Russell Szmulewitz,Everett Vokes,Mark Ratain,Peter O’Donnell
DOI: https://doi.org/10.2147/jpr.s488416
IF: 2.8319
2024-12-17
Journal of Pain Research
Abstract:Youngwoo Cho, 1 Theodore Karrison, 2 Matthew M Jack, 3 Anish R Choksi, 3, 4 Randall W Knoebel, 3, 4 Kiang-Teck J Yeo, 1, 5 Samuel L Volchenboum, 6 Russell Z Szmulewitz, 1, 7 Everett E Vokes, 7 Mark J Ratain, 1, 3, 7 Peter H O'Donnell 1, 3, 7 1 Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, IL, USA; 2 Biostatistics, Department of Health Service, University of Chicago, Chicago, IL, USA; 3 Center for Personalized Therapeutics, University of Chicago, Chicago, IL, USA; 4 Department of Pharmacy, University of Chicago Medicine, Chicago, IL, USA; 5 Department of Pathology, University of Chicago Medical Center and Biological Sciences, Chicago, IL, USA; 6 Department of Pediatrics, University of Chicago, Chicago, IL, USA; 7 Section of Hematology/Oncology, Department of Medicine, University of Chicago Medical Center and Biological Sciences, Chicago, IL, USA Correspondence: Peter H O'Donnell, Email Background: Cancer patients frequently suffer from pain, often managed with opioids. However, undertreated pain remains a significant concern. Opioid effectiveness varies due to genetic differences in how individuals metabolize some of these medications. While prior research suggests promise in tailoring opioid prescriptions based on CYP2D6 genetic makeup, its application in cancer pain management remains limited. This study investigates the potential benefits of preemptive CYP2D6 genotyping for cancer patients initiating opioid therapy, focusing on codeine, tramadol, and hydrocodone, whose efficacy is demonstrably impacted by CYP2D6 variations. Methods: This is a randomized, prospective study to evaluate the effects of preemptive pharmacogenomic (PGx) testing on opioid dosing decisions/selections and composite pain score in oncology patients. Patients with metastatic solid tumors for whom near-future opioid therapy is anticipated will be randomized to PGx and control arms, stratified by the presence or absence of bony metastases and history of opioid use. In the PGx arm, patients will be preemptively tested using a panel of pharmacogenomic genetic variants, and providers will receive opioid dosing guidance via an electronic medical record-embedded clinical decision support tool. In the control arm, pain prescribing will occur per standard of care without genotype information. Planned Outcome: The primary study outcome will be composite pain intensity during the first 45 days after an index opioid prescription for codeine, tramadol, or hydrocodone. Safety will be assessed by comparing opioid-related adverse event rates between the two study arms. Secondary outcomes will include rates of hospitalization/emergency room visits, cumulative morphine equivalents received, and type of first opioid prescribed. Keywords: pharmacogenomics, CYP2D6 , codeine, tramadol, hydrocodone, genetic testing, pain score Pain is a common and distressing symptom that can have a significant impact on the lives of people with cancer. A recent systemic review shows that about 39% of cancer patients experience pain after curative treatment, 55% during anticancer treatment, and 66% in advanced, metastatic, or terminal disease. 1 Despite its high prevalence in the patient population, numerous studies indicate a problem of analgesic undertreatment in cancer. 2 It is well documented that the effectiveness of pain therapies varies from patient to patient, even for those with similar pain levels or disease status. 3 To safely and effectively control cancer pain, it is important to have a thorough knowledge of the pharmacokinetics and pharmacodynamics of opioids and utilize this understanding to guide selection and dosing. 4 Nevertheless, current pain prescribing for oncology patients often follows a predictable pattern, in which oncologists typically use a codeine-containing medication, tramadol, or hydrocodone as the "first-line opioid analgesic. 5 " CYP2D6 is a major drug-metabolizing enzyme that is responsible for breaking down a quarter of all prescribed drugs. 6 The corresponding gene is highly polymorphic, leading to different metabolizer phenotypes in patients, and it is thus one of the key pharmacokinetic biomarkers for predicting drug response in patients. 7 Notably, numerous studies have indicated that these differences in CYP2D6 gene expression are responsible for the interindividual variability in safety and efficacy of different pain medications, including but not limited to code -Abstract Truncated-
clinical neurology